title: Evaluation of bepridil efficacy by electrophysiologic testing in patients with recurrent ventricular tachycardia: comparison of two regimens.
abstract: The purpose of the study was to evaluate this effect of different doses of intravenous and oral bepridil on the induction of ventricular tachycardia. Thirty-eight patients underwent electrophysiologic evaluation for recurrent ventricular tachycardia (VT). Sustained monomorphic VT was induced by programmed ventricular stimulation, using up to three extrastimuli in all patients. The effects of intravenous bepridil (2 mg/kg) were evaluated during the initial study. Intravenous bepridil prevented the induction of sustained VT in eight patients (21%). Electrophysiologic study was repeated after oral bepridil. In six patients the study was stopped because of adverse effects or VT recurrence. Thirty-two patients underwent repeat study 7 days later, taking oral bepridil, 500 mg/day (n = 16) or 900/day (n = 16). A dose of 500 mg/day of bepridil prevented the induction of sustained VT in only one patient. A dose of 900 mg/day of bepridil prevented the induction of sustained VT in eight patients. There were no significant clinical adverse effects, except in one patient receiving intravenous bepridil. The response to intravenous bepridil did not predict the response to oral bepridil. The response to intravenous or oral bepridil was not related to the plasma level of bepridil but was related to a higher left ventricular ejection fraction. Eight patients (21%) in whom VTs were noninducible on oral bepridil were discharged on 300 mg/day of bepridil if their initial loading dose was 500 mg/day or on 600 mg/day if their initial loading dose was 900 mg/day. They remained free of VT during a follow-up of at least 6 months.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiology, Nancy, France.
authors.forename: B
authors.initials: B
authors.lastname: Brembilla-Perrot
authors.forename: E
authors.initials: E
authors.lastname: Aliot
authors.forename: J
authors.initials: J
authors.lastname: Clementy
authors.forename: P
authors.initials: P
authors.lastname: Cosnay
authors.forename: P
authors.initials: P
authors.lastname: Djiane
authors.forename: J P
authors.initials: JP
authors.lastname: Fauchier
authors.forename: S
authors.initials: S
authors.lastname: Kacet
authors.forename: D
authors.initials: D
authors.lastname: Lellouche
authors.forename: P
authors.initials: P
authors.lastname: Mabo
authors.forename: M
authors.initials: M
authors.lastname: Richard
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D015764:Bepridil / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D004594:Electrophysiology; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D013318:Stroke Volume / Q000187:drug effects; D013617:Tachycardia, Supraventricular / Q000517:prevention & control*
chemical_list: D015764:Bepridil